Author + information
- Xumin Guan1,
- Xiao Lei Yang1,
- Yi Heng Yang1,
- Xin Tao Li1,
- Khalid BinWaleed1,
- Rong Feng Zhang1,
- Xiang Gao2,
- Si Yan Zhan3,
- Ying Liu1,
- Hui Hua Li1,
- Shou Ling Wu4 and
- Yun Long Xia1
- 1Department of Cardiology, First affiliated Hospital of Dalian Medical University, Dalian, China
- 2Department of Nutritional Sciences, The Pennsylvania State University, PA, USA
- 3School of Public Health, Peking University, Beijing, China
- 4Department of Cardiology, Kailuan General Hospital, Tangshan, China
Cardiovascular disease and cancer are the two leading causes of death worldwide. Our objective was to further investigate the associations of serum high-density lipoprotein cholesterol(HDL-C) with atherosclerosis cardiovascular disease(ASCVD) and cancer occurrence among Chinese adults in Kailuan cohort.
We prospectively examined the associations of serum high-density lipoprotein cholesterol(HDL-C) with ASCVD and cancer occurrence among 92997 Chinese adults in Kailuan cohort who were free of ASCVD and cancer at baseline(2006 to 2007). They were followed for 7.9 years until cancer diagnosis or death or until December 31 in 2014. Hazard ratio(HR) and their 95% confidence intervals(CI) for ASCVD or cancer incidence was evaluated by Cox proportional hazards regression models according to the level of HDL-C. Multivariable analysis adjusted for age, gender, cigarette smoking, alcohol consumption, physical activity, total cholesterol(TC), hypertension, diabetes mellitus and BMI at baseline.
A total of 92997 Chinese adults in Kailuan cohort were followed up 7.9 years, there were 3338(3.6%) participants developed ASCVD(3.6%) and 2370(2.6%) participants developed cancer during follow-up. HDL-C level was categorized as <1.23mmol/L, 1.23-1.42mmol/L, 1.42-1.60mmol/L, 1.60-1.84mmol/L and ≥1.84mmol/L according to quintiles of HDL-C. The participants in the fourth group(HDL-C:1.60-1.84mmol/L) had the lowest ASCVD and cancer incidence. In multivariable analysis, compared with the fourth group, the lowest quintile(<1.23mmol/L) of HDL-C increased 19% risk of ASCVD(HR 1.19, 95% CI 1.06-1.33); the upper-most quintile (≥1.84mmol/L) of HDL-C increased 22% risk of cancer(HR 1.22, 95% CI 1.07-1.38).
In this Kailuan cohort study, we found that high level of HDL-C was associated with increasing cancer risk. And consistent with previous study, low level of HDL-C was associated with increasing ASCVD risk. Thus, we should pay more attention to the potential health risks of HDL-C level and lipid modifying therapy. Large prospective trials and further experiments are needed to confirm these results and interpret these mechanisms.